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Abstract 
Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) are age-related 
conditions that are increasing in prevalence, commonly coexist, and share clinical features. This 
review provides a practical update on the epidemiology, pathophysiology, diagnosis, and 
management of patients with concomitant HFpEF and AF. Epidemiological studies highlight the 
close and complex links between HFpEF and AF, the shared risk factors, the high AF occurrence 
in the natural history of HFpEF, and the independent contribution of each condition to poor 
outcomes. Diagnosis of HFpEF in the setting of AF is challenging because the symptoms 
overlap. AF is associated with changes in echocardiographic parameters and circulating 
natriuretic peptides that confound HFpEF diagnosis. Symptomatic improvement with diuretic 
therapy supports the presence of HFpEF in patients with concomitant AF. Important knowledge 
gaps need to be addressed by a multidisciplinary and translational research approach, in order to 
develop novel therapies that can improve prognosis.  
 
<KW>Key words: Age; Diagnosis; Epidemiology; Natriuretic Peptides, Outcomes 
 
Abbreviations and Acronyms  
AF = atrial fibrillation 
ANP = atrial natriuretic peptide 
HF = heart failure 
HFpEF = heart failure with preserved ejection fraction 
HFrEF = heart failure with reduced ejection fraction 
LA = left atrium/atrial 
LV = left ventricular  
LVEF = left ventricular ejection fraction 
NT-proBNP = N-terminal B-type natriuretic peptide 
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Introduction 
Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) are 
common conditions that are increasing in prevalence, and are associated with increased 
morbidity and mortality compared with patients without these diagnoses (1). HFpEF is as 
common as heart failure with reduced ejection fraction (HFrEF), and patients suffer from similar 
symptoms, yet lack therapeutic options with proven efficacy (2). Patients with AF are 
heterogeneous and share many common clinical features with patients with heart failure (HF), 
but demonstrate a requirement for specific management in order to improve outcomes, over and 
above related comorbidities (3). Both HFpEF and AF are associated with older age, 
hypertension, and diastolic dysfunction; therefore, these disorders are inextricably linked, both to 
each other and to adverse cardiovascular outcomes (1). AF is a potent and independent 
prognostic factor in patients with HF, increasing the risk of death in clinical trials and 
observational studies (4,5). The development of AF may have more of an impact in patients with 
HFpEF than in those with HFrEF (6,7), identifying a subgroup of patients with more advanced 
HFpEF and worse exercise tolerance (8). Although the combination of AF and HFpEF appears to 
be associated with lower mortality than AF and HFrEF, patients have similar rates of incident 
stroke and HF hospitalization (9). Furthermore, the severity of disease in HFpEF and HFrEF may 
not have been comparable in prior studies. At the very least, AF and HF require comparable 
attention. 
Not all studies have been able to differentiate whether HFpEF or AF comes first, and 
there are clear diagnostic challenges in clinical practice. Identifying prevalent AF in the context 
of HFpEF is relatively straightforward, with well-documented electrocardiographic methods that 
apply to a wide range of patient populations (10). However, AF is often paroxysmal, frequently 
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asymptomatic, and can be easily missed (11). HFpEF remains a clinical diagnosis (12,13), 
combining typical symptoms and signs with echocardiographic evidence of diastolic dysfunction 
and “preserved” left ventricular ejection fraction (LVEF). Importantly, symptoms like dyspnea, 
fatigue, and impaired exercise tolerance are also the predominant symptoms of patients with AF, 
and largely overlap with HFpEF, making definitive diagnosis on the basis of clinical features 
more complex. There is ambiguity in echocardiographic diagnosis, both for the LVEF cutoff 
(which is a continuum), and the objective evaluation of diastolic function, which is not always 
easy or possible to demonstrate, particularly in the context of AF. Circulating levels of 
biomarkers, such as N-terminal B-type natriuretic peptides (NT-proBNPs) are also independently 
influenced by both conditions, making it unclear what NT-proBNP levels to use for the diagnosis 
of one condition in the presence of the other (2). 
In this review, we aim to focus on the epidemiology, pathophysiology, diagnosis, and 
management of patients with concomitant HFpEF and AF. We start by summarizing available 
evidence regarding the prevalence and incidence of HFpEF in the setting of AF and vice versa, 
and then examine the underlying mechanisms by which AF begets HFpEF and HFpEF begets 
AF. Further, we address the diagnostic uncertainties of each condition in the presence of the 
other, and consider potential therapeutic strategies. Our objective is to provide clinicians with a 
practical guide to the key issues, and address the knowledge gaps that prevent optimal treatment 
of this common and high-risk group of patients. 
Incidence and prevalence of HFpEF in the setting of AF 
Data on the incidence and prevalence of clinical HF in patients with AF is widely 
available, however specific studies on HFpEF are scarce. The PREVEND (Prevention of Renal 
and Vascular End-Stage Disease) study is a community-based cohort in the Netherlands.  Of 
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8,265 participants studied, 265 developed AF (total follow-up 80,352 person-years). The 
incidence rate of HFpEF (LVEF >50%) per 1,000 person-years was 4.90 for those with AF 
versus 0.85 for those without AF, a hazard ratio (HR) of 4.8 (1). AF was identified as a major 
risk factor for new-onset HFpEF in the Framingham Heart Study (HR: 2.5), and the presence of 
AF tended to predict incident HFpEF (HR: 2.3) more strongly than in HFrEF (14). Furthermore, 
among participants with AF, there was a higher incidence of HFpEF in women compared to men 
(35.1 vs. 21.2 events/1,000 person-years) (15). Surveys, registries, and trials give further insight 
the prevalence of HFpEF is in patients with AF, which varies between 8% and 24% (16-19), and 
depends on the definition (LVEF above 40% or 50%), and the type of AF (Figure 1). Although 
different definitions of HFpEF were used, it would seem prudent to suggest that HFpEF is more 
common in those with a longer duration of AF. 
Incidence and prevalence of AF in the setting of HFpEF 
Large epidemiological studies have established that HF is a potent risk factor for incident 
AF, with a 6-fold increase in the risk of developing AF in a previous report from the 
Framingham Heart Study (20). In fact, AF is the most common arrhythmia in HF, present in 
around one-third of patients (21,22). The prevalence of AF increases with HF severity, ranging 
from 5% in mild HF to 50% in severe HF (23). Specifically for HFpEF, the prevalence of AF 
varies between 15% and 41% (Figure 2). 
The temporal progression of AF in HFpEF was described in 939 participants with newly 
diagnosed HFpEF in the Olmsted County population cohort. Two-thirds experienced AF during 
the course of their disease: 29% prior to diagnosis, 23% concurrent with HFpEF, and 15% after 
diagnosis (24). Participants with prevalent AF at the time of HFpEF diagnosis (compared to 
sinus rhythm) were older and had higher NT-proBNP levels and larger left atria, whereas those 
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with incident AF after HFpEF diagnosis had greater diastolic dysfunction. More recently, a study 
of the temporal associations of AF and HFpEF versus HFrEF showed that participants with 
HFpEF were more likely to have prevalent AF compared to HFrEF (32% vs. 23%, p = 0.002) 
and AF at any time (62% vs. 55%, p = 0.02) (15). In aggregate, these studies highlight the close 
and complex links between HFpEF and AF, the extraordinarily high occurrence of AF in the 
natural history of HFpEF, and the independent contribution of each condition to poor outcomes 
in affected patients. 
Shared pathophysiology 
Given that a substantial proportion of patients with HFpEF experience AF at some point 
during the course of their disease, shared pathophysiological mechanisms are highly likely. 
These may involve: 1) common risk factors and comorbidities that predispose to both conditions 
simultaneously; 2) mechanisms by which HFpEF gives rise to AF; and 3) mechanisms by which 
AF leads to HFpEF (Figure 3). Noncardiac comorbidities are often present in HFpEF. 
Pulmonary disease, diabetes mellitus, anemia, and obesity tend to be more prevalent in HFpEF 
patients, but renal disease and sleep-disordered breathing burdens are similar to HFrEF (25). 
These comorbidities are also frequently present in the setting of AF (26). 
Common risk factors predisposing to both HFpEF and AF simultaneously 
Common risk factors prominently shared between HFpEF and AF include advanced age 
and age-related comorbidities, such as hypertension, obesity, and sleep apnea. Vascular-
ventricular stiffening, the hallmark of aging (27), plays an important role in the pathophysiology 
of HFpEF via left ventricular (LV) diastolic dysfunction and systolic ventricular-vascular 
uncoupling (28,29). Similarly, the incidence of AF increases sharply with age (30), and age-
related diastolic dysfunction has been shown to contribute to AF in the general population 
7 
(31,32). Importantly, however, the incidence of AF in HFpEF exceeds that expected by aging 
alone (incidence rate of 69 cases/1,000 person-years in Olmsted County HFpEF (24) compared 
with 28.3/1,000 person-years in U.S. Medicare beneficiaries ≥65 years of age) (30).  
Systemic inflammation may also link HFpEF and AF, with a new paradigm proposing 
HFpEF as an inflammatory disorder in which comorbidities, such as obesity, trigger widespread 
endothelial dysfunction, oxidative stress, and microvascular inflammation, leading to end-organ 
manifestations, such as diastolic dysfunction (33,34). Evidence supporting the hypothesis of 
endothelial microvascular inflammation in HFpEF accumulates, although definitive clinical trial 
data are still lacking. Histological findings in atrial biopsies support  the proinflammatory milieu 
of HFpEF as a key mechanism underlying AF occurrence and maintenance (35). In patients 
undergoing AF ablation, levels of inflammatory markers, such as C-reactive protein, interleukin-
6, and matrix metalloprotease-2, differed significantly between those who remained in sinus 
rhythm after ablation versus patients who reverted to AF (36). 
Mechanisms by which HFpEF gives rise to AF 
The most commonly recognized mechanism by which HFpEF gives rise to AF is via 
structural and functional remodeling of the left atrium (LA). LA volumes are 68% larger in 
HFpEF compared with age-matched controls, and 40% larger than in patients with hypertensive 
heart disease without HF (37). Patients with HFpEF have reduced emptying fractions and 
contractile reserve, compared with controls and patients with hypertension. LA enlargement in 
HFpEF is a well-established proarrhythmic substrate associated with atrial fibrosis (38). 
Abnormal distribution of gap junctions and loss of cell-to-cell coupling in areas of fibrosis 
contributes to electrical remodeling, increased atrial refractoriness, and development of AF 
(39,40). Disrupted ion-channel regulation has been demonstrated in experimental models of HF, 
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with reduction in the L-type calcium ion (Ca2+) current, the sensitive transient outward potassium 
ion (K+) current and the slow delayed rectifier K+ current in atrial myocytes (41), whereas the 
transient inward sodium ion (Na+)/Ca2+ exchanger current is increased (42). The increase in the 
Na+/Ca2+ transmembrane exchange channel current gives rise to delayed afterdepolarizations, 
leading to arrhythmias initiated by triggered activity (43). The important role of gap junctions in 
atrial remodeling has also been highlighted, involving atrial connexin proteins (44) and the 
resultant inhomogeneity of impulse propagation, thus establishing re-entry circuits predisposing 
to AF. Although many of these seminal AF studies were performed in HFrEF models, the 
underlying concepts also apply to atrial remodeling in the setting of HFpEF. 
Up-regulation of the adrenergic and renin-angiotensin-aldosterone systems have been 
shown in experimental models to contribute to impaired impulse propagation, atrial fibrosis, and 
AF in HF. Because both neuroendocrine systems are similarly up-regulated in HFpEF and in 
HFrEF (45), these mechanisms may underlie the development of AF in HFpEF. A further 
consideration includes the role of atrial natriuretic peptide (ANP), the hormone produced by the 
atria in response to stretch, which causes diuresis and vasodilation. Impaired natriuresis has been 
shown to contribute to volume overload among patients with preclinical diastolic dysfunction 
(46). Although normally important for homeostasis, failure of the atrium to secrete adequate 
amounts of ANP in HFpEF may be associated with atrial structural remodeling and mechanical 
dysfunction (47). Interestingly, atrial endocrine failure may be addressed by blocking neprilysin, 
the neutral endopeptidase that breaks down ANP. 
Mechanisms by which AF gives rise to HFpEF 
Because AF itself causes LA dilation, impaired atrial function, and atrial fibrosis, AF 
may be a direct cause of HFpEF (48). Indeed, successful cardioversion is associated with 
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restoration of atrial booster pump function and improved ventricular filling, with the atrial 
contribution to ventricular filling increasing from 30% to 47% one month after the return of 
sinus rhythm (49). AF is also associated with LV myocardial fibrosis (50), which, in turn, 
contributes to diastolic dysfunction and HFpEF (51). Furthermore, atrioventricular annular 
remodeling with progressive mitral and tricuspid regurgitation may be another mechanism by 
which AF causes HFpEF (52). Also, depletion of ANP, which may occur in permanent AF, may 
lead to more vasoconstriction and congestion, and set the stage for incident HFpEF (53).  
A mechanism often proposed to explain the development of HF in AF is that of 
tachycardia or irregularity-induced cardiomyopathy, including hemodynamic changes (shortened 
diastasis, reduced cardiac output), structural effects (LV eccentric remodeling, subendocardial 
fibrosis, impaired myocardial perfusion), cellular impact (cytoskeletal alteration, matrix and 
mitochondrial disruption, abnormal calcium handling), and neurohormonal activation (up-
regulation of the renin-angiotensin-aldosterone and natriuretic peptides) (54,55). However, these 
mechanisms classically pertain to HFrEF, and their contribution to HFpEF remains poorly 
understood. It is also possible that some cases of so-called HFpEF with AF may be patients in 
whom LVEF has recovered with adequate heart rate control. 
Diagnostic uncertainty 
Diagnosing HFpEF in the context of AF is challenging. HF remains a clinical syndrome 
characterized by the concordance of: 1) clinical symptoms and signs; 2) objective evidence of 
LV diastolic dysfunction; 3) increased circulating natriuretic peptide levels; and 4) response to 
therapy (12,56). The first 3 diagnostic components are difficult to establish in the presence of AF 
because symptoms of HF resemble those of AF, echocardiographic parameters of diastolic 
dysfunction are more challenging to obtain, and natriuretic peptide levels are elevated in patients 
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with AF, even in the absence of HF. Although reduced LVEF in AF patients can be diagnosed 
with different cardiac imaging modalities, identifying HFpEF requires a combination of 
heterogeneous echocardiographic parameters (57). As a result, there is often clinical reluctance 
to categorically state the presence of HFpEF in coexisting AF. Furthermore, there is considerable 
variation in the definition of HFpEF regarding the cutoff of LVEF (2). Although current 
guidelines recommend LVEF ≥50%, such definitions are arbitrary and may not apply to 
individual patients. The last of the 4 diagnostic components, response to therapy, seems of 
potential value, yet is underutilized in HFpEF and AF. Diuretic therapy may provide 
symptomatic benefit in patients with AF, concomitant HFpEF, and signs of fluid overload (58). 
Although there are no controlled trials available, improved fluid balance and symptom relief with 
diuretic therapy, in the absence of any change in heart rate or rhythm, are powerful clinical 
indicators of the presence of HFpEF in AF patients (Central Illustration). 
Echocardiography and natriuretic peptides 
A number of studies have demonstrated elevated filling pressures in AF, and have 
validated echocardiographic parameters in AF patients against invasive pulmonary capillary 
wedge pressure and clinical outcomes. For example, E/e’ was significantly associated with filling 
pressure (5 studies with n = 444; correlation 0.47 to 0.79) (59-63), and independently associated 
with mortality (64), exercise capacity (65), prior ischemic stroke (66), and quality of life (67). A 
number of other diastolic indexes also correlate with invasive filling pressure, such as isovolumic 
relaxation time (IVRT), mitral deceleration time, diastolic flow progression (E/Vp), and 
pulmonary venous flow measures (68). These results confirm that HFpEF (i.e., the presence of 
elevated LV filling pressure and HF symptoms) does exist in patients with AF and can be 
diagnosed, albeit from small observational studies with highly selective inclusion. 
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The difficulty in making definitive diagnoses of diastolic dysfunction by 
echocardiography or the presence of HF by elevated levels of natriuretic peptides lies in AF 
being a known modifier of the relationship between each of these variables and HFpEF. For 
example, in the case of HFpEF and DproBNP, AF is related to HFpEF and also independently 
leads to elevation of NT-proBNP, thus potentially distorting the relationship between HFpEF and 
NT-proBNP. As a result, it remains unclear which NT-proBNP cutoff to use for the diagnosis of 
HFpEF in the setting of AF, and to what extent NT-proBNP levels respond to treatment (2). 
Similarly, dilation and dysfunction of the LA, which, in sinus rhythm, is a useful diagnostic 
criterion for HFpEF (69), may be pre-existing in patients with AF. In most clinical cases, the 
diagnosis of diastolic dysfunction requires categorizing patients using a range of different 
parameters (70), not all of which will be abnormal, thus creating clinical uncertainty. These are 
also critical challenges in designing clinical trials for HFpEF and AF. 
Prognosis of concomitant AF and HFpEF 
Both prevalent and incident AF are associated with increased mortality in HFpEF (HRs: 
1.30 and 2.45, respectively, compared with patients with no AF) (24). Conversely, the presence 
of HF substantially worsens the prognosis in patients with AF (71,72). However, the type of HF 
may have different effects on different outcomes. In a meta-analysis of 10 studies, all-cause 
mortality was significantly higher in patients with HFrEF and AF than in those with HFpEF and 
AF (risk ratio 1.24, 95% CI: 1.12 to 1.36; p < 0.001; n = 45,100), whereas HF hospitalization and 
incident stroke were similar, regardless of ejection fraction (9). In the I-PRESERVE (Irbesartan 
in Heart Failure With Preserved Ejection Fraction) trial, stroke rates in HFpEF patients were 
doubled in those with a history of AF, regardless of whether they were in AF at the time of 
assessment (73). Sex differences in HFpEF were also noted in I-PRESERVE, with a greater 
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adverse prognostic effect of AF in women compared with men (74). In observational studies, 
patients in sinus rhythm with HFrEF had markedly worse symptoms, functional capacity, and 
quality of life compared to patients with HFpEF, whereas in AF patients, there were no 
differences between HFrEF and HFpEF (75). 
Current and future treatment opportunities 
There are no treatments for patients with HFpEF and AF that have been shown to 
improve prognosis, aside from anticoagulation (26,76). HF therapies that reduce mortality and 
morbidity in HFrEF, such as angiotensin-converting-enzyme inhibitors, angiotensin-receptor 
blockers, and mineralocorticoid-receptor antagonists, do not have the same impact in HFpEF 
(77-79). The added consequences of AF may also neutralize the mortality benefit of other 
therapies, such as beta-blockers or digoxin (5,80). 
Anticoagulation in AF patients is required when patients have clinical risk factors for 
stroke or thromboembolism, and current guidelines highlight the risk associated with both 
HFrEF and HFpEF on the basis of growing evidence that stroke rates are increased in AF 
patients with either type of HF (9,81,82). Although no trial has specifically randomized AF 
patients with HFpEF to anticoagulation, subgroup data from the nonvitamin K antagonist oral 
anticoagulant (NOAC) trials suggest similar efficacy in patients with and without HF (83). 
Other treatments of concomitant HFpEF and AF aim to reduce symptoms and improve 
quality of life (Central Illustration). The mainstay of management is therefore to optimize fluid 
balance, control blood pressure, and avoid ischemia, in addition to managing comorbidities, such 
as obesity, airway diseases, and diabetes (3). Aggressive risk factor management programs, 
including weight loss, have reduced AF recurrences and symptoms in AF patients (84-87) and 
improved cardiorespiratory fitness in HFpEF patients (88). This supports the notion that 
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adequate treatment of comorbidities and risk factors may improve symptom burden, quality of 
life, and improve exercise capacity. Rate control of AF in the context of HFpEF is not expected 
to improve hard endpoints, and any benefit with regard to quality of life, exercise capacity, or 
cardiac function are yet to be determined, including in older patients, who form the majority of 
this group (89). Some data suggest reduced symptoms with rate control, although the AF 
populations assessed were not specifically those with HF or HFpEF (90,91). In elderly patients 
with severe symptoms related to HFpEF and AF, it seems reasonable to start with rate control to 
optimize ventricular filling time and prevent symptoms related to paroxysms of rapid AF. 
Adopting a rhythm control strategy is challenging in patients with HFpEF; often patients are of 
advancing age and have multiple other comorbidities that may influence the success and risk of 
complications. Nevertheless, from a small single-center study, catheter ablation in HFpEF was 
associated with improved diastolic function in patients who maintained sinus rhythm (albeit with 
multiple procedures and/or antiarrhythmic drugs) (92). Early rhythm control strategies, which are 
currently under investigation, may increase the beneficial effects on symptom burden, and 
potentially improve prognosis (93). More advanced AF ablation techniques, including hybrid 
epicardial and endocardial ablation, offer promise for reducing the AF burden, even in patients 
with advanced atrial remodeling, such as those with HFpEF.  
Emerging medical therapies offer a glimmer of hope (94). In view of potential atrial 
endocrine failure in HFpEF with AF (discussed earlier) and the utility of neprilysin inhibitors to 
restore ANP levels, it is noteworthy that the angiotensin receptor-neprilysin inhibitor LCZ696 
reduced LA volume in HFpEF in the PARAMOUNT (Prospective comparison of ARNI with 
ARB on Management Of heart failUre with preserved ejectioN fracTion) phase II trial (95). 
LCZ696 was equally effective in improving outcomes in the presence or absence of AF in the 
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PARADIGM-HF trial (Prospective comparison of ARNI with ACEi to Determine Impact on 
Global Mortality and morbidity in Heart Failure) in patients with HFrEF (96). 
Implantable cardiac devices may also affect the prognosis in patients with HFpEF, with 
and without AF. Sudden cardiac death accounts for a sizeable proportion of deaths in HFpEF 
trials (97,98); however, uncertainty remains regarding the true incidence of sustained ventricular 
tachyarrhythmia and arrhythmic death in the general HFpEF population. Clarifying this 
uncertainty is of great importance because this may set the stage for implantable defibrillator 
therapies in HFpEF. The VIP-HF (Ventricular tachyarrhythmia detection by Implantable Loop 
Recording in Patients with Heart Failure and Preserved Ejection Fraction) registry is currently 
recruiting patients, and is due to report in late 2018 (99). Whether cardiac resynchronization 
therapy (CRT) is beneficial in HFpEF with and without AF needs to be determined. Substudies 
of CRT trials have shown that patients with less severe LV dysfunction (LVEF >35%) appeared 
to derive clinical and structural benefit from resynchronization (100). However, as mechanical 
dyssynchrony in HFpEF differs from that seen in classical HFrEF indications (101), the value of 
CRT in HFpEF patients with AF needs to be explored in future trials. 
Knowledge gaps 
Despite the increasing understanding of HFpEF and AF separately, there are still 
important knowledge gaps. Further study is essential to advance our understanding of the 
pathogenesis, risk, prevention, and treatment of concomitant HFpEF and AF. In Table 1 we 
summarize knowledge gaps and potential future research topics, such as defining the global 
burden of AF in HFpEF and vice versa, identifying genomic and nongenomic risk factors, 
determining the clinical effect of rate versus rhythm control, and clarifying optimal heart rate 
targets. To address these questions, we advocate multidisciplinary and translational research 
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programs capitalizing on experimental studies, observational community-based cohorts, and 
clinical trials. There are also opportunities for future research in the area of diagnosis, 
particularly new cardiac imaging techniques, novel clinical indexes, and measures of LA 
function. 
Summary and conclusions 
Although HFpEF and AF frequently coexist, there are still numerous unanswered 
questions about the pathophysiology, symptomatology, diagnosis, and prognosis of both 
conditions when occurring together. More systematic research is urgently needed to answer these 
unresolved issues, and to provide treatments that can improve quality of life and reduce adverse 
clinical outcomes in the rapidly expanding number of patients with HFpEF and AF.
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FIGURE LEGENDS 
Central Illustration: Diagnosis and Management of Concomitant HFpEF and AF  
*The ratio of mitral peak E velocity to tissue Doppler e’: >15 septal and >13 lateral are 
associated with adverse outcomes in AF patients. Other indexes are also helpful, such as mitral 
deceleration time, isovolumic relaxation time and pulmonary venous flow. Note that 
echocardiographic determination of diastolic dysfunction is different in patients with AF due to 
the lack of mitral inflow A wave, loss of pulmonary venous flow A reversal and different 
“normal value: ranges compared to sinus rhythm (e.g., diminution of pulmonary venous systolic 
flow in AF).  †NT-proBNP ≥600 pg/ml, as used in the SOCRATES-Preserved study 
(NCT01951638), or >900 pg/ml, used in the PARAGON-HF trial (NCT01920711). AF = atrial 
fibrillation; ECG = electrocardiogram; HFpEF = heart failure with preserved ejection fraction; 
NOAC = nonvitamin K antagonist oral anticoagulant; VKA = vitamin K antagonist oral 
anticoagulant.   
Figure 1: Prevalence of HFpEF in AF 
The prevalence of HFpEF in 4 major AF trials. The percentage with left ventricular ejection 
fraction above 40% or 50% is indicated in the columns, as is the type of AF. AF = atrial 
fibrillation; HFpEF = heart failure with preserved ejection fraction. 
Figure 2: Prevalence of AF in HFpEF 
The prevalence of AF in HFpEF varies in 7 large heart failure trials. Abbreviations as in Figure 
1. 
Figure 3: Pathophysiology and Shared Mechanisms in HFpEF and AF.  
Common mechanisms involved in HFpEF, AF, and the combination of these conditions. ANP = 
atrial natriuretic peptide; LV = left ventricular; RAAS = renin-angiotensin-aldosterone system. 
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Other abbreviations as in Figure 1. 
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Table 1. Knowledge Gaps and Areas Essential for Advancing Understanding of the 
Pathogenesis, Prevention, and Treatment of Concomitant HFpEF and AF 
Research Domain Important Knowledge 
Gaps 
Areas of Potential Discovery and 
Scientific Advancement 
Epidemiology Incidence and prevalence 
of HFpEF in the setting of 
AF. 
Global burden of HFpEF 
and AF. 
Identification of the clinical, subclinical, 
and genomic factors underlying 
variability in AF and HFpEF, life course, 
and complications in diverse racial 
groups, populations and regions. 
Discovery of strategies to prevent AF 
onset and progression in the setting of 
HFpEF, and vice versa. 
Noninvasive imaging Diagnosis of HFpEF in the 
setting of AF. 
Novel methods for assessing diastolic 
function and, in particular, for 
quantifying LA function are within reach. 
Measuring LA volume using 3-
dimensional echocardiography, 
quantifying LA function with speckle-
based strain and velocity vector imaging 
(102). 
Natriuretic peptides Optimal cutoff values for 
diagnosis of HFpEF in 
Clinical classification of patients to 
enable stratified therapy and a more 
33 
patients with AF. personalized approach. 
Clinical cardiology Treatment of AF in the 
setting of HFpEF. 
Treatment of HFpEF in the 
setting of AF. 
Investigation of rate and rhythm control 
in AF and HFpEF, and improvement in 
symptom burden and prognosis. 
Confirmation that the benefits of physical 
activity and lifestyle modification seen in 
HFpEF (88) and AF (87) also occur in 
patients with both conditions. 
Development of novel therapeutic agents 
in patients with HFpEF that are also 
beneficial in those with concomitant AF. 
Further data on patient care managed by 
hemodynamic monitoring (103) 
Investigation of device therapies in AF 
and HFpEF. 
Systems biology Relations between clinical 
risk factors, genetics, and 
environment.  
 
Integration across multiple disciplines 
(basic science, epidemiological, clinical, 
bioinformatics) will accelerate our 
understanding of complex pathways 
underlying AF and HFpEF, and develop 
opportunities for prevention and 
treatment. 
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AF = atrial fibrillation; HFpEF = heart failure with preserved ejection fraction; LA = left 
atrium/atrial 
Diagnosis of atrial brillation (AF) and 
heart failure with preserved ejection fraction (HFpEF)
Treatment recommendations
for AF and HFpEF
Symptoms
Breathlessness
Fatigue
Orthopnea
Nocturnal dyspnea
Investigations
AF on ECG or device
Left atrial enlargement
Increased E/e ratio on echo*
Increased natriuretic peptides†
Clinical response to diuretics
HFpEF AF Combined
Signs
Increased venous pressure
Rales/third heart sound
Irregular pulse
Prognostic
Anticoagulation with NOACs or VKA
(all patients ≥65 years or other risk factors)
Disease modifying
• Anti-hypertensive therapy
• Treatment of myocardial ischemia
• Management of associated comorbidities
Symptomatic therapy
• Diuretics
• Heart rate control (resting <110 bpm;
lower if ongoing symptoms)
• AF rhythm control
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